title: Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma.
abstract: OBJECTIVE
  Functional studies have demonstrated that nuclear factor (NF)-kappaB promotes tumour progression in ovarian cancer cells. However, surprisingly little is known of the expression of effectors of the NF-kappaB pathway in human ovarian cancer in vivo.
  
  
  RESULTS
  Immunohistochemistry and in situ hybridization revealed that in a cohort of 85 primary ovarian carcinomas, total p65 expression was inversely correlated to nuclear and cytoplasmic phospho-IkappaBalpha (P = 0.002 and P = 0.05, respectively), and IkappaBalpha mRNA expression (P = 0.032). In contrast, phospho-p65 expression was paralleled by the expression of nuclear (P = 0.027) and cytoplasmic phospho-IkappaBalpha (P = 0.01). Total p65 expression was an adverse prognostic factor for overall survival (P = 0.018). In contrast, total IkappaBalpha and phosphorylated nuclear and cytoplasmic IkappaBalpha expression were favourable prognostic markers (P = 0.001, P = 0.031, P = 0.001, respectively). Cytoplasmic phospho-IkappaBalpha expression remained a significant prognostic factor on multivariate analysis (P = 0.010). In cultured, stimulated OVCAR-3 ovarian cancer cells the cytoplasmic retranslocation of p65 was delayed by inhibition of the nuclear membrane transporter chromosomal region maintenance/exportin1 protein (CRM1). A positive association of p65 and CRM1 expression was demonstrated in ovarian cancer tissue (P < 0.0001).
  
  
  CONCLUSIONS
  Total and phosphorylated IkappaBalpha protein expression might serve as markers for NF-kappaB activation in human ovarian carcinoma. Cytoplasmic localization of p65 may be related to deregulated nucleocytoplasmic transport in carcinomas overexpressing CRM1.
authors.affiliation: Institute of Pathology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin. silvia.darb-esfahani@charite.de
authors.forename: Silvia
authors.initials: S
authors.lastname: Darb-Esfahani
authors.forename: Bruno V
authors.initials: BV
authors.lastname: Sinn
authors.forename: Wilko
authors.initials: W
authors.lastname: Weichert
authors.forename: Jan
authors.initials: J
authors.lastname: Budczies
authors.forename: Annika
authors.initials: A
authors.lastname: Lehmann
authors.forename: Aurelia
authors.initials: A
authors.lastname: Noske
authors.forename: Ann-Christin
authors.initials: AC
authors.lastname: Buckendahl
authors.forename: Berit Maria
authors.initials: BM
authors.lastname: Müller
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Dominique
authors.initials: D
authors.lastname: Koensgen
authors.forename: Balazs
authors.initials: B
authors.lastname: Györffy
authors.forename: Manfred
authors.initials: M
authors.lastname: Dietel
authors.forename: Carsten
authors.initials: C
authors.lastname: Denkert
mesh_terms: D002277:Carcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D015331:Cohort Studies; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020672:I-kappa B Proteins / Q000235:genetics / Q000378:metabolism; D007150:Immunohistochemistry; D028884:Karyopherins / Q000235:genetics / Q000378:metabolism; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation; D012333:RNA, Messenger / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism; D000097606:Exportin 1 Protein
chemical_list: D020672:I-kappa B Proteins; D028884:Karyopherins; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D051996:Transcription Factor RelA; D000097606:Exportin 1 Protein; C000606204:NFKBIA protein, human